DRAFT | June 2019

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		We did not use antibodies.

批注 [Office1]: place a"✖"in the column if not applicable.

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		We did not use cell materials.
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		We did not use primary cultures.

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		We did not use animals.
Animal observed in or captured from the field: Provide species, sex and age where possible		We did not use animals.
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		We did not use model organisms.

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		We did not use plants.
Microbes: provide species and strain, unique accession number if available, and source		We did not use microbes.

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 10, line 7-12, Methods, Para 1	
Provide statement confirming informed consent obtained from study participants.		Informed consent was not obtained in each subject due to the observational analysis of hospitalized patients.
Report on age and sex for all study participants.	Page 15, line 13-14, Results, Para 1, and Table 1.	

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		The current study is not a clinical trial.

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		There are no detailed step-by-step protocols.

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination		We did not carry out sample size determination because this is a retrospective observational study.
Randomisation		We did not carry out randomization due to its observational study.
Blinding		We did not carry out blinding.
Inclusion/exclusion criteria	Page 9, line 9-12 and page 10, line 1-7, Methods, para 1	

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		We did not perform experiment.
Define whether data describe technical or biological replicates	Page 10, line 14-page 14, line 7, Methods, para 2-9	

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 10, line 7-12, Methods, para 1	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		This study did not use animals.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		This study did not involve specimen and field samples.

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		This study is not subject to DURC.

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Page 10, line 1-6, Methods, para 1	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Page 14, line 9-page 15, line 9, Methods, para 10-11	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		We have to obtain approval from the research ethics committee for data sharing. Since the research ethics committee does not allow data sharing in general, it may be hard to share data
If data are publicly available, provide accession number in repository or DOI or URL.		We have to obtain approval from the research ethics committee for data sharing. Since the research ethics committee does not allow data sharing in general, it may be hard to share data
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		This study did not use publicly available data.

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		There was no newly generated code or software.
If code is publicly available, provide accession number in repository, or DOI or URL.		There was no newly generated code or software.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

批注 [Office2]: Please place "ICMJE" at least.

ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.

Article Information: http://dx.doi.org/10.21037/cdt-20-1024